Immunonutrition vs EPA-DHA Enriched Nutritional Support in Patients With Cancer Undergoing Surgery (Immunonutritio)
IMMUNONUTRITION VS EPA-DHA ENRICHED NUTRITIONAL SUPPORT IN PATIENTS WITH CANCER UNDERGOING SURGERY
To compare clinical and molecular effects of nutritional support (immunonutrition or EPA-DHA enriched oral nutritional supplements) in patients with cancer undergoing surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jose Carlos Garrido, PhD
- Phone Number: 957 736 571
- Email: josecarlos.garrido@imibic.org
Study Locations
-
-
Córdoba
-
Córdoba, Córdoba, Spain, 14004
- Recruiting
- IMIBIC
-
Contact:
- Aura Herrera
- Email: aurita.dhm@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis
Description
Inclusion Criteria:
- Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis)
Exclusion Criteria:
- End-stage liver disease
- End-stage kidney disease
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with cancer undergoing surgery (primary tumor location: gastrointestinal tract, ovary)
Patients undergo nutritional prehabilitation before surgery |
Patients will receive nutritional advice and 2 oral nutritional supplements with arginine, fatty acids and nucleotides Patients will receive nutritional advice and 2 oral nutritional supplements enriched with EPA and DHA |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body composition changes
Time Frame: 1-3 months
|
changes in fat mass, fat-free mass, lean mass and phase angle |
1-3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cytokines changes
Time Frame: 1-3 months
|
Changes in circulating cytokines (IL6, IL8, MIP10) |
1-3 months
|
|
Metabolites changes
Time Frame: 1-3 months
|
Changes in circulating metabolites including lipids and muscle-related metabolites |
1-3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Immunonutrition vs EPA-DHA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.